Your browser doesn't support javascript.
loading
Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer.
Jeon, Youngbae; Sym, Sun Jin; Yoo, Bong Kyu; Baek, Jeong-Heum.
Afiliación
  • Jeon Y; Division of Colon and Rectal Surgery, Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
  • Sym SJ; Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
  • Yoo BK; College of Pharmacy, Gachon University, Incheon, Republic of Korea.
  • Baek JH; Division of Colon and Rectal Surgery, Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
Integr Cancer Ther ; 21: 15347354221105498, 2022.
Article en En | MEDLINE | ID: mdl-35695002
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias del Recto / Neoplasias Colorrectales / Neoplasias del Colon / Curcumina / Ginsenósidos Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Integr Cancer Ther Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias del Recto / Neoplasias Colorrectales / Neoplasias del Colon / Curcumina / Ginsenósidos Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Integr Cancer Ther Año: 2022 Tipo del documento: Article